Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL ON CLINICAL TRIAL APPLICATION FOR THE ADDITION OF NEW INDICATIONS OF TRILACICLIB FOR INJECTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT IN RELATION TO

THE APPROVAL ON CLINICAL TRIAL APPLICATION FOR THE

ADDITION OF NEW INDICATIONS OF TRILACICLIB FOR INJECTION

This announcement is made by Simcere Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the "Board") of directors ("Directors", and each a "Director") of the Company is pleased to announce that, on April 9, 2021, Trilaciclib for injection, the innovative pharmaceutical being developed by the Group in collaboration with G1 Therapeutics, INC., has obtained the approval on clinical trial application for the addition of new indications issued by the National Medical Products Administration, PRC (中國國家藥品監督管理局). According to the approval, the Group plans to initiate, jointly with its partner G1 Therapeutics, INC., phase three randomized and double-blind clinical trial of comparing Trilaciclib to placebo used in patients with metastatic colorectal cancer treated with FOLFOXIRI/bevacizumab.

ABOUT G1 THERAPEUTICS, INC.

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies intended to improve the lives of those affected by cancer, including its first commercially available product COSELATM, a first-in-class therapy designed to improve outcomes for patients being treated with chemotherapy.

- 1 -

ABOUT THE COMPANY

The Company is a company engaged in the R&D, production and commercialization of pharmaceuticals with the national key laboratory of translational medicine and innovative pharmaceuticals. The Company has a diversified product portfolio in strategically focused therapeutic areas, including, (i) oncology, (ii) central nervous system diseases and (iii) autoimmune diseases, with leading positions in their respective therapeutic segments and/or established track record. The Company continues to source innovative therapies globally and established extensive strategic partnership with several multinational companies.

By order of the Board of

Simcere Pharmaceutical Group Limited

Mr. Ren Jinsheng

Chairman and executive Director

Hong Kong, April 16, 2021

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.

- 2 -